Rossello, XavierRodriguez-Sinovas, AntonioVilahur, GemmaCrisóstomo, VerónicaJorge, InmaculadaZaragoza, CarlosZamorano, José LBermejo, JavierOrdoñez, AntonioBoscá, LisardoVazquez, JesusBadimón, LinaSánchez-Margallo, Francisco MiguelFernández-Avilés, FranciscoGarcia-Dorado, DavidIbáñez, Borja2020-01-292020-01-292019-12-30Sci Rep. 2019; 9(1):202902045-2322http://hdl.handle.net/20.500.12105/8988Despite many cardioprotective interventions have shown to protect the heart against ischemia/reperfusion injury in the experimental setting, only few of them have succeeded in translating their findings into positive proof-of-concept clinical trials. Controversial and inconsistent experimental and clinical evidence supports the urgency of a disruptive paradigm shift for testing cardioprotective therapies. There is a need to evaluate experimental reproducibility before stepping into the clinical arena. The CIBERCV (acronym for Spanish network-center for cardiovascular biomedical research) has set up the "Cardioprotection Large Animal Platform" (CIBER-CLAP) to perform experimental studies testing the efficacy and reproducibility of promising cardioprotective interventions based on a pre-specified design and protocols, randomization, blinding assessment and other robust methodological features. Our first randomized, control-group, open-label blinded endpoint experimental trial assessing local ischemic preconditioning (IPC) in a pig model of acute myocardial infarction (n = 87) will be carried out in three separate sets of experiments performed in parallel by three laboratories. Each set aims to assess: (A) CMR-based outcomes; (B) histopathological-based outcomes; and (C) protein-based outcomes. Three core labs will assess outcomes in a blinded fashion (CMR imaging, histopathology and proteomics) and 2 methodological core labs will conduct the randomization and statistical analysis.engVoRhttp://creativecommons.org/licenses/by/4.0/Atribución 4.0 Internacional31889088912029010.1038/s41598-019-56613-62045-2322Scientific reportsopen access